Roth Capital analyst Jerry Isaacson started InMed Pharmaceuticals with a Buy rating and C$1.10 price target ($.825 USD). The company is developing a bacterial platform for the biosynthesis of medically relevant cannabinoids as well as a portfolio of cannibinoid treatments for diseases with "high unmet medical need," Isaacson tells investors in a research note. He believes InMed's platform has the potential to deliver some natural cannabinoids in cost-effective quantities for clinical and commercial development.
News 
Market Data 
Discover 
AI
